GlassScriptPhysician profile
Tarek Nafee
NPI 1730740838
$2,690.95
in general payments reported to CMS, 2019-2025
21 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $165 · 2021: $11.71 · 2022: $250 · 2023: $351 · 2024: $284 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Grant: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.92 |
| Grant | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $529.35 | 2023-2025 | Optis, Jot Dx, Cardiomems |
| Boston Scientific Corporation | $410.00 | 2023-2025 | Avvigo Guidance System, Synergy, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.51 | 2020-2025 | Lifevest |
| Abiomed | $210.51 | 2023-2025 | Impella |
| Cook Incorporated | $200.00 | 2025 | |
| Pfizer INC. | $140.45 | 2019-2025 | |
| Inari Medical, INC. | $137.20 | 2019 | |
| Radius Health, INC. | $124.79 | 2019 | |
| Cvrx, INC. | $100.30 | 2024 | Barostim Neo System |
| Insmed, INC. | $89.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.81 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.46 | 2024-2025 | Camzyos |
| Alexion Pharmaceuticals, INC. | $52.75 | 2019 | |
| Cook Medical LLC | $52.63 | 2025 | Zilver Ptx |
| Novo Nordisk INC | $50.00 | 2025 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $42.79 | 2023 | Alphavac |
| Getinge USA Sales, LLC | $23.71 | 2023 | Cardiosave Hybrid, Type B Plug |
| Takeda Pharmaceuticals U.S.A., INC. | $21.81 | 2022 | |
| Janssen Biotech, INC. | $20.00 | 2019 | |
| Gilead Sciences, INC. | $14.62 | 2020 | |
| Merck Sharp & Dohme LLC | $14.26 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Nafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.